Clinical Cancer Research CR Helping Patients Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, M. H.
Right arrow Articles by Bates, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, M. H.
Right arrow Articles by Bates, S. E.
Clinical Cancer Research Vol. 7, 1610-1617, June 2001
© 2001 American Association for Cancer Research

Regular Articles

The P-Glycoprotein Antagonist PSC 833 Increases the Plasma Concentrations of 6{alpha}-Hydroxypaclitaxel, a Major Metabolite of Paclitaxel1

Min H. Kang, William D. Figg2, Yuichi Ando, Mikhail V. Blagosklonny, David Liewehr, Tito Fojo and Susan E. Bates

Medicine Branch [M. H. K., W. D. F., Y. A., M. V. B., T. F., S. E. B.] and Biostatistics and Data Management Section [D. L.], Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: Overexpression of P-glycoprotein (Pgp) is one mechanism of drug resistance in cancer chemotherapy. A Phase I trial was conducted using PSC 833, a Pgp antagonist, in combination with paclitaxel in patients with refractory cancer. The objective of this study was to assess the effect of PSC 833 on the metabolism of paclitaxel and characterize the differences in 6{alpha}-hydroxypaclitaxel pharmacokinetics. In addition, we examined the possibility of enhanced cytotoxicity of paclitaxel by the coexistence of 6{alpha}-hydroxypaclitaxel.

Experimental Design: Patients received paclitaxel 35 mg/m2/day by continuous intravenous infusion (CIVI) x 4 days without PSC 833 in cycle 1 and escalating doses of paclitaxel (13.1, 17.5, or 21.3 mg/m2/day CIVI x 4 days) with 5 mg/kg PSC 833 by mouth every 6 h x 7 days in cycle 2. Plasma samples were analyzed for both paclitaxel and its major metabolite with high-performance liquid chromatography methods. Using human liver microsomes, we studied the effect of PSC 833 on the metabolism of paclitaxel. In addition, the in vitro cytotoxicity of 6{alpha}-hydroxypaclitaxel alone and in combination with paclitaxel was evaluated.

Results: Twenty-one of 22 patients had a metabolite peak (6{alpha}-hydroxypaclitaxel) observed in the chromatogram of plasma samples from cycle 2 when they received paclitaxel in combination with PSC 833. This metabolite was not detectable in plasma obtained during the first cycle when they received paclitaxel without PSC 833. During cycle 2, the mean concentrations of 6{alpha}-hydroxypaclitaxel and paclitaxel were 0.10 ± 0.074 and 0.079 ± 0.041 µg/ml, respectively. A moderate association was observed between total bilirubin and 6{alpha}-hydroxypaclitaxel concentrations (P = 0.015, r = 0.52; n = 21). Human liver microsome experiments showed that a PSC 833 concentration as high as 10 µM did not affect the production of 6{alpha}-hydroxypaclitaxel. Paclitaxel cytotoxicity in HL60 and K562 human leukemia cells was increased in the presence of noncytotoxic concentrations of 6{alpha}-hydroxypaclitaxel.

Conclusions: PSC 833 increases the plasma concentration of 6{alpha}-hydroxypaclitaxel during paclitaxel therapy. Inhibition of cytochrome P-450 3A4 by PSC 833 may explain this in part, although other mechanisms cannot be excluded.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Pgp3 is a multidrug transporter that is expressed in normal tissues, including the apical surface of intestinal epithelia, endometrial glands, the blood-brain barrier, and the proximal tubule of the kidney (1 , 2) . Although the physiological function of Pgp is not known, it has been suggested that Pgp may play a role in defense against xenobiotics in normal tissues (3) . Overexpression of Pgp, which is encoded by the MDR1 gene, confers multidrug resistance in cancer cells (4) . In patients, overexpression can correlate with a poor prognosis (5, 6, 7, 8, 9, 10) . A number of chemotherapeutic agents including the Vinca alkaloids, the anthracyclines, the taxanes, and other natural products have been identified as substrates for Pgp (11) . In addition, numerous antagonists have been identified including verapamil, cyclosporine A, quinidine, and several potent second-generation antagonists, currently under clinical investigation. PSC 833, a cyclosporine D analogue, is a nonimmunosuppressive, nonnephrotoxic Pgp antagonist (12) . Biotransformation of PSC 833 is CYP3A dependent (13) .

Paclitaxel was originally isolated from the bark of the Pacific yew tree and was subsequently identified as an antineoplastic agent (14) . Paclitaxel stabilizes microtubules resulting in cell cycle arrest. Clinical trials have documented paclitaxel activity against ovarian, breast, lung, and other types of cancer (15, 16, 17, 18, 19) . Paclitaxel metabolism has been characterized in several studies with three major metabolites identified: 6{alpha}-hydroxypaclitaxel, 3'-p-hydroxypaclitaxel, and 6{alpha},3'-p-dihydroxypaclitaxel. CYP2C8 is responsible for the transformation of paclitaxel to 6{alpha}-hydroxypaclitaxel and the formation of 6{alpha},3'-p-dihydroxypaclitaxel from 3'-p-hydroxypaclitaxel (20, 21, 22, 23) . CYP3A4 converts paclitaxel to 3'-p-hydroxypaclitaxel and also converts 6{alpha}-hydroxypaclitaxel to 6{alpha},3'-p-dihydroxypaclitaxel (Fig. 1Citation ; Ref. 24 ).



View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Chemical structure of paclitaxel and its metabolites (left) and the metabolic pathways for paclitaxel biotransformation (right). Paclitaxel: R1 = H, R2 = H; 6{alpha}-hydroxypaclitaxel: R1 = OH, R2 = H; 3-p-hydroxypaclitaxel: R1 = H, R2 = OH; 6{alpha},3-p-dihydroxypaclitaxel: R1 = OH, R2 = OH (modified from Ref. 24 ).

 
A Phase I trial combining oral PSC 833 and infusional paclitaxel in patients with advanced cancer was conducted at the National Cancer Institute (25) . The objectives of the study were to determine the maximum tolerated dose of PSC 833 in combination with paclitaxel and to compare the pharmacokinetics of paclitaxel administered alone with the pharmacokinetics of paclitaxel with concomitant administration of PSC 833. Four different dose levels of PSC 833 ranging from 1.25 to 5 mg/kg p.o. every 6 h x 7 days were explored. Fifty patients received paclitaxel and PSC 833 separately in the first cycle and a combination of paclitaxel and PSC 833 in subsequent cycles. The maximum tolerated doses identified were: 5 mg/kg PSC 833 administered every 6 h x 7 days in combination with a paclitaxel dose of either 13.1 mg/m2/day by CIVI x 4 days without filgrastim or 17.5 mg/m2/day CIVI x 4 days with filgrastim. Paclitaxel doses of 13.1 or 17.5 mg/m2/days CIVI x 4 days with PSC 833 resulted in mean plasma concentrations that were equivalent to those achieved with a paclitaxel dose of 35 mg/m2/days CIVI x 4 days without PSC 833. However, considerable interpatient variation was observed in the magnitude of paclitaxel concentration changes with PSC 833.

In the course of analyzing patient plasma samples, we observed, in a majority of patients who received 5 mg/kg PSC 833 administered p.o. every 6 h, unusually high concentrations of a metabolite subsequently identified as 6{alpha}-hydroxypaclitaxel. A peak corresponding to 6{alpha}-hydroxypaclitaxel was not detected in the first cycle when paclitaxel was administered alone. This study describes the identification of this metabolite as 6{alpha}-hydroxypaclitaxel and its quantification. Attempts to understand the mechanisms responsible for the appearance of the metabolite and to find a correlation between the metabolite and the occurrence of toxicities are also discussed.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Clinical Protocol.
Eligible patients were >18 years of age and had a Karnofsky performance status of 70% or better, a life expectancy of >3 months, aspartate aminotransferase and alanine aminotransferase <=2 x upper limit of normal, creatinine clearance >=50 ml/min, WBC >=3,000/mm3, ANC >=1,000/mm3, and platelet count >=100,000/mm3. Patients who had received chemotherapy, immunotherapy, or radiation therapy in the 4 weeks before study entry, or had undergone a prior bone marrow transplantation or extensive radiation resulting in compromised bone marrow reserve, were not eligible. Agents proven to interact with CsA or suspected to interact with P-glycoprotein were restricted during the study. The protocol was approved by the Institutional Review Board of the National Cancer Institute, and all patients signed an informed consent document prior to treatment.

The trial was a Phase I dose escalation study in which both PSC 833 and paclitaxel were escalated. Paclitaxel dose of 13.1 mg/m2/day by CIVI x 4 days in combination with PSC 833 at 5 mg/kg every 6 h was established as the maximum tolerated dose. Then, to support an advance of the paclitaxel dose, filgrastim was added to the regimen. The maximum tolerated dose with the support of filgrastim was determined as 17.5 mg/m2/day by CIVI x 4 days in combination with PSC 833 5 mg/kg every 6 h. For this report, the analysis was confined to patients who received a paclitaxel dose of 35 mg/m2/day CIVI x 4 days without concurrent PSC 833 in cycle 1 and 5 mg/kg PSC 833 every 6 h x 7 days with a paclitaxel dose of either 13.1, 17.5, or 21.3 mg/m2/day CIVI x 4 days in cycle 2. Patients receiving both drugs in cycle 2 started PSC 833 3 days prior to the start of the paclitaxel infusion and received PSC 833 until the end of the paclitaxel infusion, when both drugs were discontinued.

Sampling Schedule.
Serial blood samples were collected for phamacokinetic analysis. Blood samples were drawn in heparinized tubes prior to treatment and at 24, 48, 72, and 96 h after the start of the paclitaxel infusion in the first and second cycle. Up to 96 h after infusion, blood samples were drawn from one patient. Samples were centrifuged immediately, and the plasma was collected and stored at -80°C until analysis.

Analytical Methods.
The concentrations of paclitaxel and 6{alpha}-hydroxypaclitaxel in plasma was determined using HPLC with UV detection, as described previously (26) . A Hewlett-Packard 1090 Series II liquid chromatograph equipped with a photodiode-array detector was used. Paclitaxel was extracted from 0.6 ml of plasma, with 200 ng/ml harmine added as an internal standard. 0.6 ml of 0.2 M ammonium acetate was added to the plasma, and solid-phase extraction was performed using a C18 elution column (Varian). The columns were equilibrated with 2 ml of methanol, followed by 2 ml of 10 mM ammonium acetate (pH 5.0). The plasma-buffer mixtures were loaded onto the columns, and the columns were washed with 2 ml of 10 mM ammonium acetate, followed by 2 ml of 20% methanol in 10 mM ammonium acetate and 1 ml of n-hexane. The columns were dried and eluted with 2 x 1 ml of 0.1% triethylamine in acetonitrile. The eluents were dried and reconstituted in 200 µl of acetonitrile:methanol:water (4:1:5 v/v/v) containing 0.01 M ammonium acetate. The reconstituted sample, 170 µl, was injected onto a Waters Nova-Pak C18 (3.9 x 300 mm) column. The mobile phase (25% acetonitrile, 5% methanol, 70% water in 10 mM NH4Ac) with gradient was used at a flow rate of 1.0 ml/min at room temperature. UV detection was at 230 nm (bandwidth, 10 nm).

Enzymatically produced 6{alpha}-hydroxypaclitaxel and 3-p-hydroxypaclitaxel were obtained from Gentest Co. (Woburn, MA). The content of a vial was dissolved in 500 µl of methanol. The final concentration was determined by absorbance at 230 nm using a molar extinction coefficient of 26.2 mM-1. The concentrations used for the standard curve ranged from 20 to 300 ng/ml. The plasma concentrations of 6{alpha}-hydroxypaclitaxel were measured using the same analytical method used for paclitaxel. Average retention times were 13.3, 12.6, and 9.7 min for paclitaxel, 6{alpha}-hydroxypaclitaxel, and the internal standard, harmine, respectively. The limits of quantification were 25 ng/ml for paclitaxel and 20 ng/ml for 6{alpha}-hydroxypaclitaxel. The intraassay and interassay coefficients of variation for paclitaxel were <10% between 25 and 100 ng/ml. The intraassay and interassay coefficients of variation for 6{alpha}-hydroxypaclitaxel over the entire concentration range were <6.2 and 6.7%, respectively.

Human Liver Microsome Experiment.
PSC 833 was kindly provided by Novartis, Inc. (East Hanover, NJ). The purity of PSC 833 was >98%. Ketoconazole, CsA, NADP+, glucose-6-phosphate, and glucose-6-phosphate dehydrogenase were purchased from Sigma Chemical Co. (St. Louis, MO). Pooled human liver microsomes were purchased from Gentest Co. A reaction mixture consisted of: (a) 300 µl of a 2:1 mixture of 0.5 M sodium-potassium phosphate buffer (pH 7.4):0.5 mM EDTA; (b) 100 µl of NADPH-regenerating system (2 mM NADP+, 40 mM MgCl2, 40 mM glucose 6-phosphate, and 10 units/ml glucose 6-phosphate dehydrogenase); (c) 0.5 mg (25 µl) of human liver microsomes; and (d) distilled water to make a final volume of 1 ml after adding inhibitors and the substrate. CsA, PSC 833, or ketoconazole at the concentrations of 0.1, 0.3, 1, 3 and 10 µM were added to tubes to yield the final vehicle concentration of 0.5%. After a 5-min preincubation with inhibitors at 37°C in a shaking water bath, 10 µl of 1 mM paclitaxel (10 µM in a final concentration) were added and incubated for additional 20 min. The reaction was terminated by adding 5 ml of cold acetonitrile containing the internal standard. The sample was vortexed and centrifuged. The organic phase was evaporated to dryness, and the residue was reconstituted with 200 µl of the mobile phase. The analysis using HPLC is described in "Analytical Methods." Calibration curves of 6{alpha}-hydroxypaclitaxel and 3'-p-hydroxypaclitaxel were made to measure the absolute concentrations of each metabolite. Control incubations were performed in the absence of the regenerating system or in the absence of microsomal protein. The production of 6{alpha}-hydroxypaclitaxel was linear up to a final paclitaxel concentration of 20 µM or 20 min of incubation time.

Cytotoxicity (MTT) Assay.
HL60 and K562 human leukemia cell lines were obtained from American Type Culture Collection (Manassas, VA) and cultivated in RPMI 1640 plus 10% FBS. Paclitaxel was a Bristol-Myers product. Cells (15,000) in 100 µl plated in each well of 96-well flat-bottomed plate were exposed to increasing concentrations of paclitaxel, 6{alpha}-hydroxypaclitaxel, or both added in 100 µl of the medium. After 3 days, 20 µl of 5 mg/ml MTT solution in PBS were added to each well for 2 h. After removal of the medium, 170 µl of DMSO were added to each well to dissolve the formazan crystals. The absorbance at 540 nm was determined using a Biokinetics plate reader (Bio-Tek Instruments, Inc., Winooki, VT). Triplicate wells were assayed for each condition, and SDs were determined.

Statistical Analyses.
A Spearman rank correlation coefficient (r) was used to evaluate the association between the concentrations of total bilirubin and those of maximum concentrations of 6{alpha}-hydroxypaclitaxel (in all cases the highest observed concentrations were at the end of the infusion) or steady-state concentrations of paclitaxel (determined by the mean of the concentration at 48, 72, and 96 h of infusion). The total bilirubin levels measured within 24 h after the last dose of PSC 833 were used for statistical analysis. To compare patients who did or did not receive filgrastim with respect to toxicities including neutropenia, thrombocytopenia, and liver toxicity in relation to the maximum concentrations of 6{alpha}-hydroxypaclitaxel, a Cochran-Armitage trend test was used. In addition, among patients who did not receive filgrastim during cycle 1 or cycle 2, the difference in percentage of decrease of ANC from baseline (delta) between the two cycles was formed by subtraction (delta = % decrease in cycle 2 - % decrease in cycle 1; n = 10) and tested for equality to zero with the Wilcoxon signed rank test.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Forty-five patients received a paclitaxel dose of 35 mg/m2/day CIVI x 4 days in cycle 1. Of these, 22 patients completed at least the second cycle in which they received a PSC 833 dose of 5 mg/kg every 6 h x 7 days. These 22 patients included 12 females and 10 males with a median age of 56 years and a range of 35–67. The paclitaxel doses administered concurrently with PSC 833 in the second cycle were 13.1 mg/m2/day CIVI x 4 days in 6 patients, 17.5 mg/m2/day CIVI x 4 days in 14 patients, and 21.3 mg/m2/day CIVI x 4 days in 2 patients.

Pharmacokinetics of 6{alpha}-Hydroxypaclitaxel.
Examination of the HPLC chromatogram revealed the appearance of a metabolite peak in the second cycle when paclitaxel was administered with PSC 833. This peak was subsequently identified as 6{alpha}-hydroxypaclitaxel by demonstrating the same retention time and UV absorbance wavelength as 6{alpha}-hydroxypaclitaxel. The chemical structure of paclitaxel and its metabolites, and the metabolic pathways of paclitaxel biotransformation, are shown in Fig. 1Citation . In the first cycle, when patients received paclitaxel alone, 6{alpha}-hydroxypaclitaxel was not detectable. However, a metabolite peak corresponding to 6{alpha}-hydroxypaclitaxel appeared in the second cycle when patients received concomitant PSC 833 and paclitaxel. Fig. 2Citation shows the chromatograms of plasma obtained from a patient during cycles 1 and 2. In cycle 2, paclitaxel and 6{alpha}-hydroxypaclitaxel peaks are observed during the paclitaxel infusion and up to 24 h after the discontinuation of the infusion. As seen here, in some patients, the 6{alpha}-hydroxypaclitaxel peak was higher than the paclitaxel one. The concentrations of paclitaxel and 6{alpha}-hydroxypaclitaxel from the first cycle and second cycles from the same patient are plotted in Fig. 3Citation . Twenty-four h after the initiation of the paclitaxel infusion, 6{alpha}-hydroxypaclitaxel was quantifiable. As the infusion continued, the concentration of 6{alpha}-hydroxypaclitaxel increased and at 72 h was higher than paclitaxel. The metabolite reached a maximum concentration 2 h after the end of the infusion in this patient. The maximum concentrations of 6{alpha}-hydroxypaclitaxel obtained with paclitaxel doses of 13.1, 17.5, and 21.3 mg/m2/day CIVI x 4 days plus 5 mg/kg PSC 833 every 6 h x 7 days are shown in Table 1Citation . The concentrations of 6{alpha}-hydroxypaclitaxel increased during the 96-h infusion (Fig. 4)Citation . The mean steady-state concentration, Cpss, and clearance of paclitaxel from C1 is reported previously (25) .



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. HPLC chromatogram of plasma obtained from a patient in cycles 1 and 2. A, cycle 1, 1–2 min prior to end of paclitaxel infusion; B, cycle 2, prior to paclitaxel infusion; C, cycle 2, 1–2 min prior to end of paclitaxel infusion. 6-OH PTX: 6{alpha}-hydroxypaclitaxel. I.S., the internal standard, harmine.

 


View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Concentration versus time profile from a representative patient. Time after the initiation of the paclitaxel infusion is plotted on the X axis. The paclitaxel and 6{alpha}-hydroxypaclitaxel plasma concentrations are plotted on the same scale on the Y axis. •, paclitaxel concentrations from cycle 1; {blacktriangleup}, paclitaxel concentrations from cycle 2; {blacksquare}, 6{alpha}-hydroxypaclitaxel concentrations from cycle 2.

 

View this table:
[in this window]
[in a new window]

  		Table 1 The concentrations of 6{alpha}-hydroxypaclitaxel and paclitaxel during infusion from cycle 2

 


View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Mean plasma concentration versus time profile of paclitaxel and 6{alpha}-hydroxypaclitaxel from cycles 1 and 2 depicting the means for paclitaxel dose of 17.5 mg/m2/day. Axes are as in Fig. 3Citation . Symbols, mean; bars, SDs. •, paclitaxel concentrations in cycle 1; {triangleup}, paclitaxel concentrations in cycle 2; {square}, 6{alpha}-hydroxypaclitaxel concentrations in cycle 2.

 
Correlation between Toxicity and Metabolites.
Hyperbilirubinemia, which has been observed previously in patients treated with CsA, was observed with PSC 833 but was not considered a dose-limiting toxicity. Fig. 5Citation presents scatterplots of bilirubin levels and the concentrations of paclitaxel (Cpss, defined as the mean of the drug concentrations at 48, 72, and 96 h) or 6{alpha}-hydroxypaclitaxel (Cmax, defined as the highest concentration during the infusion, which in all cases was the concentration at the end of infusion). As shown, the level of total bilirubin was not associated with plasma paclitaxel concentrations (Fig. 5ACitation ; P = 0.68, r = -0.09; n = 22) but was moderately associated with 6{alpha}-hydroxypaclitaxel concentrations (Fig. 5BCitation ; P = 0.015, r = 0.52; n = 21). Fig. 6Citation shows scatterplots of the toxicity grade of neutropenia and thrombocytopenia versus 6{alpha}-hydroxypaclitaxel (Cmax) concentration. For analysis, the data were divided into two groups based on filgrastim administration (n = 12 with filgrastim support; n = 10 without filgrastim). In neither group could a significant trend between 6{alpha}-hydroxypaclitaxel concentration and neutropenia be demonstrated (P = 0.12 with filgrastim; P = 0.20 without filgrastim). Similarly, no trend was observed when the concentrations of 6{alpha}-hydroxypaclitaxel and toxicity grade of thrombocytopenia were correlated (P = 0.28). The percentage of decrease of ANC in cycle 2 was also not significantly different from that in cycle 1 (P = 0.56).



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Scatterplot depicting steady-state paclitaxel concentrations (A, •) or 6{alpha}-hydroxypaclitaxel (B, {blacktriangleup}) concentrations as a function of total bilirubin concentrations. Data are from cycle 2 only. The lines do not imply a functional relationship. The total bilirubin levels used for statistical analysis were measured within 24 h after the last dose of PSC 833. Steady-state paclitaxel was determined by the mean of the drug concentrations at 48, 72, and 96 h.

 


View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Scatterplots depicting the Cmax of 6{alpha}-hydroxypaclitaxel as a function of the worst grade of toxicity for neutropenia and thrombocytopenia for each patient. {blacktriangleup}, with 5 µg/ml of filgrastim administered 48 h after the end of infusional paclitaxel/PSC 833 (n = 12); {circ}, without filgrastim support (n = 10). For the statistical analysis of neutropenia, no toxicity and grade 2 were combined in the group without filgrastim support, and no toxicity and grade 1 were combined and grade 3 and 4 were combined in the group with filgrastim support in neutropenia. Also, grade 1 and 2 were combined for the analysis of thrombocytopenia. The Cmax of 6{alpha}-hydroxypaclitaxel was determined by the highest concentrations during 96 h infusion. In all cases, this was the concentration at the end of infusion. National Cancer Institute common toxicity criteria was used to grade the toxicities. The lowest count (ANC and platelet) during the 28-day cycle was used to determine the grade of toxicity.

 
Effects of PSC 833 on the Production of 6{alpha}-Hydroxypaclitaxel.
Human liver microsome experiments were performed to evaluate whether the appearance of 6{alpha}-hydroxylation in cycle 2 was attributable to alterations in the metabolism of paclitaxel by PSC 833 (Fig. 7)Citation . Low concentrations of ketoconazole, the positive control, inhibited the formation of 3'-p-hydroxypaclitaxel (IC50 <1 µM), whereas higher concentrations reduced the production of 6{alpha}-hydroxypaclitaxel (53 ± 6.1% of control) as well as 3'-p-hydroxypaclitaxel (complete inhibition), as reported previously (27) . In contrast to ketoconazole, PSC 833 and CsA only affected the formation of 3-p-hydroxypaclitaxel (IC50: between 3 and 10 µM and between 1 and 3 µM, respectively) without substantially changing the production of 6{alpha}-hydroxypaclitaxel at concentrations ranging from 0.1 to 10 µM. This resulted in an increase in 6{alpha}-hydroxypaclitaxel relative to 3'-p-hydroxypaclitaxel.



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 7. Inhibition of microsomal paclitaxel metabolism in vitro. Concentrations of inhibitors were 0.1, 0.3, 1, 3, and 10 µM; plot represents means of three experiments; bars, SD. A, production of 6{alpha}-hydroxypaclitaxel. B, production of 3-p-hydroxypaclitaxel; •, PSC 833; {triangleup}, CsA; {circ}, ketoconazole. The production of 6{alpha}-hydroxypaclitaxel without inhibitors was 277 pmol/min/mg microsomal protein. Activity (% of control) = (production of metabolite with inhibitors)/(production of metabolite without inhibitors) x 100.

 
Cytotoxicity of Paclitaxel and 6{alpha}-Hydroxypaclitaxel.
We evaluated the cytotoxicity of paclitaxel, 6{alpha}-hydroxypaclitaxel, and a combination of both in HL60 and K562 cells (Fig. 8)Citation . 6{alpha}-Hydroxypaclitaxel alone was ~10 times less potent than paclitaxel; 20 nM (23 ng/ml) 6{alpha}-hydroxypaclitaxel was not cytotoxic. However, in the presence of 20 nM 6{alpha}-hydroxypaclitaxel, the cytotoxicity of paclitaxel was increased, especially at low paclitaxel concentrations. In both cell lines the IC50 of paclitaxel in the presence of 20 nM 6{alpha}-hydroxypaclitaxel was 2–3-fold less than the IC50 of paclitaxel alone. These observations suggest that 6{alpha}-hydroxypaclitaxel at concentrations that were achieved during cycle 2 can increase the cytotoxicity of paclitaxel in vitro.



View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 8. HL60 cells (A) and K562 cells (B) were incubated with paclitaxel alone ({circ}), 6{alpha}-hydroxypaclitaxel alone ({triangleup}), or paclitaxel plus 20 nM 6{alpha}-hydroxypaclitaxel ({blacksquare}). After 3 days, MTT assay was performed as described in "Materials and Methods." Results represent means; bars, SD.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Previous clinical trials have reported the ratio of 6{alpha}-hydroxypaclitaxel to paclitaxel after i.v. administration to be small (28, 29, 30) . Furthermore, human liver microsome experiments indicated that CsA did not affect 6{alpha}-hydroxylation of paclitaxel (31 , 32) . Given the similarity of PSC 833 and CsA metabolism (13) , we did not expect changes in plasma 6{alpha}-hydroxypaclitaxel concentrations when paclitaxel was administered with concurrent PSC 833. However, as demonstrated in the present study, we found high 6{alpha}-hydroxypaclitaxel concentrations, similar to those of paclitaxel, in the plasma of patients receiving PSC 833.

There are several possible explanations for the clinical presence of 6{alpha}-hydroxypaclitaxel, none of which are mutually exclusive. The first possibility is that the metabolic pathway via CYP3A4 is competitively inhibited by PSC 833, resulting in a shift from production of 3'-p-hydroxypaclitaxel to 6{alpha}-hydroxypaclitaxel via CYP2C8. This shift could result in increased formation of 6{alpha}-hydroxypaclitaxel and inhibition of subsequent 3'-p-hydroxylation of paclitaxel. This possibility is supported in part by the results with the human liver microsomes experiments demonstrating a concentration-dependent PSC 833 inhibition of 3'-p-hydroxylation of paclitaxel without a substantial effect on the formation of 6{alpha}-hydroxypaclitaxel (converted by CYP2C8), resulting in increased 6{alpha}-hydroxypaclitaxel relative to 3'-p-hydroxylation at concentrations >1 µM PSC 833, which are within the range achieved in the patients in this study. One could argue that 6{alpha}-hydroxylation is a major pathway of paclitaxel metabolism, and inhibiting CYP3A4 with PSC 833 may not critically affect 6{alpha}-hydroxylation. However, further metabolism of 6{alpha}-hydroxypaclitaxel by CYP3A4 may have been inhibited by PSC 833, resulting in increased 6{alpha}-hydroxypaclitaxel. Therefore, an alteration in the metabolism of paclitaxel may provide an important explanation for the increased 6{alpha}-hydroxypaclitaxel concentration in plasma.

A second explanation may be through inhibition of intestinal Pgp. The primary route of elimination of paclitaxel is via hepatic metabolism and biliary excretion (33 , 34) . Paclitaxel and its metabolites have been found in human bile (21 , 24) . Furthermore, the bioavailability of oral paclitaxel has been shown to increase up to 8-fold with coadministration of oral CsA, with an increase in the ratio of 6{alpha}-hydroxypaclitaxel:paclitaxel, as well as an increase in other metabolites (35, 36, 37) . p.o. administered PSC 833 could have increased the absorption of excreted paclitaxel and its metabolites, resulting in higher plasma concentrations by enhancing the enterohepatic circulation.

Finally, there is evidence that PSC 833 can affect bile flow rate and biliary excretion in a reversible manner (38) . Although the exact mechanism is unclear, we observed a significant correlation (P = 0.015) between total bilirubin concentrations and the concentration of 6{alpha}-hydroxypaclitaxel in plasma. It is thus possible that PSC 833 increased the reabsorption of paclitaxel metabolites, including 6{alpha}-hydroxypaclitaxel, by promoting cholestasis.

The biological activity of 6{alpha}-hydroxypaclitaxel has been investigated previously (31 , 39) . In MOLT-4 and U-937 leukemia cell lines, they found the IC50s of 6{alpha}-hydroxypaclitaxel to be 52 and 29 nM, respectively, whereas in human ovarian carcinoma (A2780) and rat colon carcinoma (CC531) cells, 50 nM 6{alpha}-hydroxypaclitaxel was inactive (39) . As a single compound, 6{alpha}-hydroxypaclitaxel was shown to be weakly myelotoxic (39) . In the present study, we observed 6{alpha}-hydroxypaclitaxel to be less cytotoxic than paclitaxel. This observation is not unexpected because hydroxylation of a cytotoxic drug is usually a detoxification process. Therefore, the clinical significance of an increase in 6{alpha}-hydroxypaclitaxel may be negligible when the ratio of 6{alpha}-hydroxypaclitaxel to paclitaxel is small, as would be expected with shorter paclitaxel infusions, where paclitaxel concentrations are high. However, the importance of 6{alpha}-hydroxypaclitaxel may be greater at lower concentrations of paclitaxel, such as might occur with longer paclitaxel infusions. Furthermore, the results of colorimetric (MTT) assays suggest that paclitaxel cytotoxicity may be greater in the presence of 6{alpha}-hydroxypaclitaxel.

In conclusion, we have found that coadministration of PSC 833 with paclitaxel increases the concentrations of both paclitaxel and 6{alpha}-hydroxypaclitaxel. Several possible explanations for the increase in 6{alpha}-hydroxypaclitaxel concentrations are discussed. The clinical significance of 6{alpha}-hydroxypaclitaxel and paclitaxel concentrations may depend on the schedule of administration. The results of this study emphasize once again that the concurrent use of a agent such as PSC 833 can considerably alter the pharmacokinetics and metabolism of chemotherapeutic agents.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the United States Government Office of Research on Minority Health. Back

2 To whom requests for reprints should be addressed, at Medicine Branch, National Cancer Institute, NIH, Building 10, Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892. Phone: (301) 402-3622; Fax: (301) 402-8606; E-mail: wdfigg{at}helix.nih.gov Back

3 The abbreviations used are: Pgp, P-glycoprotein; CIVI, continuous intravenous infusion; CYP, cytochrome P450; HPLC, high-performance liquid chromatography; ANC, absolute neutrophil count; CsA, cyclosporine A; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Back

Received 11/24/00; revised 3/ 8/01; accepted 3/13/01.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of multidrug-resistance gene product P-glycoprotein in normal tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738, 1987.[Abstract/Free Full Text]
  2. Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58: 131-171, 1989.
  3. Cordon-Cardo C., O’Brien J. P., Boccia J., Casals D., Bertino J. R., Melamed M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 38: 1277-1281, 1990.[Abstract]
  4. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 63: 385-427, 1993.[CrossRef]
  5. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tusruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphocytic leukemia cells at diagnosis. Blood, 79: 473-476, 1992.[Abstract/Free Full Text]
  6. Goasguen J. E., Dossot J-M., Fardel O., Le Mee F., Le Gall E., Leblay R., LePrise P. Y., Chaperon J., Fauchet R. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood, 81: 2394-2398, 1993.[Abstract/Free Full Text]
  7. Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 78: 586-592, 1991.[Abstract/Free Full Text]
  8. Pileri S. A., Sabattini E., Falini B., Tazzari P. L., Gherlinzoni F., Michieli M. G., Damiani D., Zucchini L., Gobbi M., Tsuruo T., Baccarani M. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology, 19: 131-140, 1991.[Medline]
  9. Pirker R., Wallner J., Geissler K., Linkesch W., Haas O. A., Bettlelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., Ludwig H., Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst., 83: 708-712, 1991.[Abstract/Free Full Text]
  10. Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A., Bennett J., Gottesman M., Pastan I. MDR1 transcripts levels as an indication of resistant disease in acute myelogenous leukaemia. Br. J. Haematol., 75: 340-345, 1990.[Medline]
  11. Kamimoto Y., Gatmaintan Z., Hsu J., Arias I. M. The function of GP-170, the multidrug resistance gene product, in rat canalicular membrane vesicles. J. Biol. Chem., 264: 11693-11698, 1989.[Abstract/Free Full Text]
  12. Keller R. P., Altermatt H. J., Nooter K., Poschmann G., Laissue J. A., Bollinger P., Hiestand P. C. SDZ PSC 833, a nonimmunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50: 593-597, 1992.[Medline]
  13. Fischer V., Rodriguez-Gascon A., Heitz F., Tynes R., Hauck C., Cohen D., Vickers A. E. The multidrug resistance modulator Valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interaction and pharmacological activity of the main metabolite. Drug Metab. Dispos., 26: 802-811, 1998.[Abstract/Free Full Text]
  14. Wani M. C., Taylor H. L., Wall N. E., Coggon P., McPhail A. T. Plant antitumor agents. IV. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93: 2325-2327, 1971.[CrossRef][Medline]
  15. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111: 273-279, 1989.
  16. Holmes F. A., Walters R. S., Theriault R. L., Forman A. D., Newton L. K., Raber M. N., Buzdar A. U., Frye D. K., Hortobagyi G. N. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83: 1797-1805, 1991.[Free Full Text]
  17. Motzer R. J., Chou T. C., Schwartz L., Bosl G. J., Bajorin D. F., Hutter H. Paclitaxel in germ cell cancer. Semin. Oncol., 22: 12-15, 1995.
  18. Murphy W. K., Fossella F. V., Winn R. J., Shin D. M., Hynes H. E., Gross H. M., Davilla E., Leimert J., Dhingra H., Raber M. N., Krakoff I. H., Hong W. K. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J. Natl. Cancer Inst., 85: 384-388, 1993.[Abstract/Free Full Text]
  19. Ajani J. A., Ilson D. H., Daugherty K., Pazdur R., Lynch P. M., Kelsen D. P. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J. Natl. Cancer Inst., 86: 1086-1091, 1994.[Abstract/Free Full Text]
  20. Cresteil T., Monsarrat B., Alvinerie P., Treluyer J. M., Vierir I., Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res., 54: 386-392, 1994.[Abstract/Free Full Text]
  21. Kumar G. N., Walle U. K., Walle T. Cytochrome P450 3A-mediated human liver microsomal Taxol 6{alpha}-hydroxylation. J. Pharmacol. Exp. Ther., 268: 1160-1165, 1994.[Abstract/Free Full Text]
  22. Harris J. W., Rahman A., Kim B-R., Guengerich F. P., Collins J. M. Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 54: 4026-4035, 1994.[Abstract/Free Full Text]
  23. Rahman A., Korekwa K. R., Grogan J., Gonzalez F. J., Harris J. W. Selective biotransformation of Taxol to 6{alpha}-hydroxytaxol by human cytochrome P450 2C8. Cancer Res., 54: 5543-5546, 1994.[Abstract/Free Full Text]
  24. Jamis-Dow C., Pearl M. L., Watkins P. B., Blake D. S., Klecker R. W., Collin J. M. Predicting drug interactions in vivo from experiments in vitro. Am. J. Clin. Oncol., 20: 592-599, 1997.[CrossRef][Medline]
  25. Chico I., Kang M. H., Bergan R., Abraham J., Bakke S., Meadows B., Rutt A., Robey R., Choyke P., Merino M., Goldspiel B., Smith T., Steinberg S., Figg W. D., Fojo T., Bates S. A Phase I study of infusional paclitaxel in combination with the Pgp antagonist PSC 833 (Valspodar). J. Clin. Oncol., 19: 832-842, 2001.[Abstract/Free Full Text]
  26. Huizing M. T., Keung A. C. F., Rosing H., van der Kuij V., ten Bokkel Huinink W. W., Mandjes I. M., Dubbelman A. C., Pinedo H. M., Beijnen J. H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. Clin. Oncol., 11: 2127-2135, 1993.[Abstract/Free Full Text]
  27. Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther., 277: 321-332, 1996.[Abstract/Free Full Text]
  28. Gianni L., Kearns C., Giani L., Capri G., Vigano L., Lacatelli A., Bonadonna G., Egorin M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-190, 1995.[Abstract/Free Full Text]
  29. Royer I., Alvinerie J., Armand L., Ho L. K., Wright M., Monsarrat B. Paclitaxel metabolites in human plasma and urine: identification of 6{alpha}-hydroxypaclitaxel, 7-epitaxol, and Taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun. Mass Spectrom., 9: 495-502, 1995.[CrossRef][Medline]
  30. Monsarrat B., Chatelut E., Royer I., Alvinerie P., Dubois J., Dezeuse A., Roche H., Cros S., Wright M., Canal P. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab. Dispos., 26: 229-233, 1998.[Abstract/Free Full Text]
  31. Harris J. W., Katki A., Anderson L. W., Chmurny G. N., Pauksteli J. V., Collin J. M. Isolation, structural determination, and biological activity of 6{alpha}-hydroxypaclitaxel, the principal human metabolite of Taxol. J. Med. Chem., 37: 706-709, 1994.[CrossRef][Medline]
  32. Kumar G. N., Oatis J. E., Jr., Thornburg K. R., Heldrich F. J., Hazard E. S., III, Walle T. 6{alpha}-Hydroxytaxol: isolation and identification of the major metabolite of Taxol in human liver microsomes. Drug Metab. Dispos., 22: 177-179, 1994.[Medline]
  33. Monsarrat B., Alvinerie P., Wright M., Dubios J., Gueritte-Voegelein F., Guenard D., Guenard D., Donehower R. C., Rowinsky E. K. Hepatic metabolism and biliary clearance of Taxol in rats and humans. Natl. Cancer Inst. Monogr., 15: 39-46, 1993.
  34. Monsarrat B., Mariel E., Cros S., Gares M., Guenard D., Gueritte-Voegelein F., Wright M. Taxol metabolism. Isolation and identification of three major metabolites of Taxol in rat bile. Drug Metab. Dispos., 18: 895-901, 1990.[Abstract]
  35. Malingre M. M., Meerum Terwogt J. M., Beijnen J. H., Rosing H., Koopman F. J., van Tellingen O., Duchin K., Huinink W. W., Swart M., Lieverst J., Schellens J. H. Phase I and pharmacokinetic study of oral paclitaxel. J. Clin. Oncol., 18: 2468-2475, 2000.[Abstract/Free Full Text]
  36. van Asperen J., van Tellingen O., van der Valk M. A., Rozenhart M., Beijnen J. H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporine A. Clin. Cancer Res., 4: 2293-2297, 1998.[Abstract/Free Full Text]
  37. Meerum Terwogt J. M., Malingre M. M., Beijnen J. H., ten Bokkel Huinink W. W., Rosing H., Koopman F. J., van Tellingen O., Swart M., Schellens J. H. Coadministration of oral cyclosporine A enables oral therapy with paclitaxel. Clin. Cancer Res., 5: 3379-3384, 1999.[Abstract/Free Full Text]
  38. Song S., Suzuki H., Kawai R., Tanaka C., Akasaka I., Sugiyoma Y. Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab. Dispos., 26: 1128-1133, 1998.[Abstract/Free Full Text]
  39. Sparreboom A., Huizing M., Boesen J. J., Nooijen W. J., van Tellingen O., Beijnen J. H. Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother. Pharmacol., 36: 299-304, 1995.[Medline]



This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
M. A. Rudek, J. Venitz, Y. Ando, E. Reed, J. M. Pluda, and W. D. Figg
Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies
J. Clin. Pharmacol., October 1, 2003; 43(10): 1124 - 1135.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. S H Lam and R. J Ignoffo
A guide to clinically relevant drug interactions in oncology
Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
W. K. Kelly, A. X. Zhu, H. Scher, T. Curley, M. Fallon, S. Slovin, L. Schwartz, S. Larson, W. Tong, B. Hartley-Asp, et al.
Dose Escalation Study of Intravenous Estramustine Phosphate in Combination with Paclitaxel and Carboplatin in Patients with Advanced Prostate Cancer
Clin. Cancer Res., June 1, 2003; 9(6): 2098 - 2107.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. E. Lovat, S. Oliverio, M. Ranalli, M. Corazzari, C. Rodolfo, F. Bernassola, K. Aughton, M. Maccarrone, Q. D. C. Hewson, A. D. J. Pearson, et al.
GADD153 and 12-Lipoxygenase Mediate Fenretinide-induced Apoptosis of Neuroblastoma
Cancer Res., September 15, 2002; 62(18): 5158 - 5167.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, M. H.
Right arrow Articles by Bates, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, M. H.
Right arrow Articles by Bates, S. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online